Methotrexate is noninferior to prednisone in improving forced vital capacity (FVC) after 24 weeks in treatment-naïve pulmonary sarcoidosis patients.
Prednisone and methotrexate show distinct side-effect profiles, with prednisone causing weight gain and insomnia, and methotrexate associated with nausea and liver-function abnormalities.
Shared decision-making considering efficacy and adverse effect profiles can optimize individualized treatment strategies in pulmonary sarcoidosis.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.